Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19
Our findings suggest that favipiravir does not have antiviral activity at the dose used in our study, and further work to understand the mechanistic basis of the drug-drug interaction with lopinavir-ritonavir is required.
Authors
- Wen Yao Mak (ORCID: https://orcid.org/0000-0002-8346-2934)
- David Lowe (ORCID: https://orcid.org/0000-0003-3332-483X)
- Laura Buggiotti (ORCID: https://orcid.org/0000-0002-7404-7800)
- Joseph Frank Standing (ORCID: https://orcid.org/0000-0002-4561-7173)
- Akosua Adom Agyeman (ORCID: https://orcid.org/0000-0002-8866-3524)
- José Afonso Guerra‐Assunção (ORCID: https://orcid.org/0000-0001-6593-403X)
- L. M. Brown
- Judith Breuer
- Japhette E. Kembou‐Ringert
- FLARE Investigators
Institutions
- RCSI & UCD Malaysia Campus (MY)
- Royal Free London NHS Foundation Trust (GB)
- Great Ormond Street Hospital (GB)
- Hospital Pulau Pinang (MY)
- The Royal Free Hospital (GB)
- Penang Adventist Hospital (MY)
- National Institutes of Biotechnology Malaysia (MY)
- Institute of Infection and Immunity (CA)
- University College London (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1002/bcp.70507
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00